Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2011. The report serves as a London Stock Exchange announcement issued on January 17, 2011, regarding a significant legal charge expected to be recorded in the fourth quarter of 2010.
Key Financial Metrics
- Legal Charge (Q4 2010): £2.2 billion ($3.4 billion).
- After-Tax Cost: £1.8 billion.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these standard financial metrics; it focuses exclusively on the specific legal provision.
Material Changes and Unusual Items
The primary material change is the announcement of a £2.2 billion legal charge for Q4 2010. This charge represents an increase in provisions for two main areas:
- US Sales and Promotional Practices: Additional provisioning related to the investigation by the US Attorney's Office for the District of Colorado.
- Avandia (Rosiglitazone) Product Liability: While a provision was taken in July 2010 for settled or received cases, the company has received a substantial number of new claims. The charge reflects the completed assessment of these additional cases and an estimate of likely future claims.
Management Commentary and Risks
PD Villarreal, SVP Global Litigation, stated that while the charge is significant, the approach to resolving long-standing legal matters is in the company's best interests. Management noted that several major cases have been closed over the last year and expressed determination to reduce litigation risk.
Risks and Contingencies:
- Provisions are based on reasonable estimates after legal advice, but ultimate liability may vary.
- Outcomes depend on litigation proceedings, investigations, and settlement negotiations.
- There is no assurance that actual losses will not exceed the reported provisions by a material amount.
- Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the impact of the £1.8 billion after-tax cost on full-year 2010 earnings per share.
- Monitor the status of the US Attorney's Office investigation into sales and promotional practices.
- Track the volume of new Avandia product liability claims received post-assessment.
- Review the "Risk Factors" section in the 2009 Annual Report on Form 20-F for detailed operational risks.